Illumina (NASDAQ:ILMN) Full Year 2024 Results
Key Financial Results
- Revenue: US$4.37b (down 2.9% from FY 2023).
- Net loss: US$1.22b (loss widened by 5.3% from FY 2023).
- US$7.69 loss per share (further deteriorated from US$7.35 loss in FY 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Illumina EPS Misses Expectations
Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 11%.
The primary driver behind last 12 months revenue was the Core Illumina segment contributing a total revenue of US$4.33b (99% of total revenue). The most substantial expense, totaling US$1.57b were related to Non-Operating costs. This indicates that a significant portion of the company's costs is related to non-core activities. Explore how ILMN's revenue and expenses shape its earnings.
Looking ahead, revenue is forecast to grow 4.7% p.a. on average during the next 3 years, compared to a 6.1% growth forecast for the Life Sciences industry in the US.
Performance of the American Life Sciences industry.
The company's shares are down 17% from a week ago.
Balance Sheet Analysis
Just as investors must consider earnings, it is also important to take into account the strength of a company's balance sheet. We have a graphic representation of Illumina's balance sheet and an in-depth analysis of the company's financial position.
New: AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities.
• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies
Or build your own from over 50 metrics.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About NasdaqGS:ILMN
Illumina
Provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa.
Excellent balance sheet with reasonable growth potential.
Similar Companies
Market Insights
Community Narratives
![Bejgal](https://media.simplywall.st/news/1706674307668-no-image.png)
![StjepanK](https://media.simplywall.st/news/1691632323732-stjepan.jpeg)
![Evangelos](https://media.simplywall.st/news/1706674307668-no-image.png)